BusinessAdamas Announces Data Presentation on ADS-5102 at the Academy of Managed Care Pharmacy 2017 Annual MeetingBy Nasdaq OMXMar 28, 2017, 5:38 PM UTC
BusinessAdamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's DiseaseBy Nasdaq OMXJan 6, 2017, 2:01 PM UTC
BusinessAdamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's DiseaseBy Nasdaq OMXJan 6, 2017, 2:01 PM UTC
BusinessAdamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with EpilepsyBy Nasdaq OMXJan 3, 2017, 9:53 PM UTC
